Reverba Successfully Exits 424 Capital Partnership

News related to:Reverba · 2 min read

WAKEFIELD, Mass., Nov. 19, 2026 /CourierPR/ -- Reverba, a global health engagement company, has successfully exited from the private equity firm 424 Capital, marking a significant milestone in the company's growth and expansion. This strategic transaction, while the terms of which were not disclosed, represents a culmination of a partnership that began in 2021 with the aim of building upon Reverba's differentiated patient-engagement capabilities and creating a broader platform serving pharmaceutical and biotechnology companies across the drug-development and commercialization lifecycle.

Nagdev highlighted the accomplishments of Cheryl Lubbert, CEO of Reverba, and the entire Reverba team, noting their efforts in strengthening the organization, expanding its capabilities, and building a more strategic partner for some of the world's leading life sciences companies.

During 424's ownership, Reverba made significant investments in its leadership team, operating infrastructure, and commercial organization. The company also expanded its capabilities through the acquisition of Six Degrees Medical, adding medical communications and healthcare professional engagement capabilities. Reverba established an international presence and extended its reach earlier into the drug-development lifecycle. These efforts broadened Reverba's offering beyond its historical patient-engagement focus, positioning the company to support life sciences clients across both patient and healthcare professional audiences.

Reverba's mission remained focused on bringing the patient voice into the development and commercialization of therapies and helping patients better understand their diseases, treatment options, and care journeys. As therapies become increasingly specialized and personalized, Reverba's work helps make complex science and treatments more understandable and meaningful to the people they are intended to serve.

Lubbert highlighted the importance of the partnership, noting that 424 shared the company's conviction in the importance of its mission and invested alongside Reverba in the people, capabilities, and infrastructure needed to serve clients and their patients in more meaningful ways.

The transaction was facilitated by Baird as the exclusive financial advisor and Whiteman Osterman & Hannah LLP as legal counsel. This exit marks a new chapter for Reverba, as the company continues to focus on its core mission and expand its reach in the life sciences industry.

Start filing today

One press release free every week. No card required.

Create a free account